<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Braz. J. Microbiol</journal-id><journal-id journal-id-type="publisher-id">bjm</journal-id><journal-title-group><journal-title>Brazilian Journal of Microbiology</journal-title></journal-title-group><issn pub-type="ppub">1517-8382</issn><issn pub-type="epub">1678-4405</issn><publisher><publisher-name>Sociedade Brasileira de Microbiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26273264</article-id><article-id pub-id-type="pmc">4507541</article-id><article-id pub-id-type="doi">10.1590/S1517-838246220131037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medical Microbiology</subject></subj-group></article-categories><title-group><article-title>Long-term evaluation of the antimicrobial susceptibility and
microbial profile of subgingival biofilms in individuals with aggressive
periodontitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Louren&#x000e7;o</surname><given-names>Talita Gomes Ba&#x000ea;ta</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref rid="c01" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Heller</surname><given-names>D&#x000e9;bora</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="aff" rid="aff02">2</xref><xref ref-type="aff" rid="aff03">3</xref></contrib><contrib contrib-type="author"><name><surname>do Souto</surname><given-names>Renata Martins</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Silva-Senem</surname><given-names>Mayra Xavier e</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Varela</surname><given-names>Victor Macedo</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>Maria Cynesia Barros</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Feres-Filho</surname><given-names>Eduardo Jorge</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Colombo</surname><given-names>Ana Paula Vieira</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="aff" rid="aff02">2</xref></contrib></contrib-group><aff id="aff01"><label>1</label>Universidade Federal do Rio de
Janeiro, Instituto de Microbiologia, Universidade Federal do Rio de
Janeiro, Rio de Janeiro, RJ, Brasil, Instituto de Microbiologia, Universidade
Federal do Rio de Janeiro, Brazil.</aff><aff id="aff02"><label>2</label>Universidade Federal do Rio de
Janeiro, Departamento de Cl&#x000ed;nica Dent&#x000e1;ria, Universidade Federal do Rio de
Janeiro, Rio de Janeiro, RJ, Brasil, Departamento de Cl&#x000ed;nica Dent&#x000e1;ria, Universidade
Federal do Rio de Janeiro, Brazil.</aff><aff id="aff03"><label>3</label>Boston University, Oral Biology Departament, Goldman School of Medicine, Boston, MA, USA, Oral Biology Departament, Goldman School of
Medicine, Boston, MA, USA.</aff><author-notes><corresp id="c01">Send correspondence to T.G.B. Louren&#x000e7;o. Instituto de Microbiologia
Paulo de G&#x000f3;es, Universidade Federal do Rio de Janeiro, Bloco I, lab. I2-03; Av.
Carlos Chagas Filho 373, Cidade Universit&#x000e1;ria, 21941-902 Rio de Janeiro, RJ,
Brazil. E-mail: <email>talitalourenco@hotmail.com</email>.</corresp><fn id="fn01" fn-type="other"><p>Associate Editor: Elizabeth de Andrade Marques</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2015</year></pub-date><volume>46</volume><issue>2</issue><fpage>493</fpage><lpage>500</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Sociedade Brasileira de
Microbiologia</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>All the content of the journal, except where otherwise noted, is
licensed under a Creative Commons License CC BY-NC.</license-p></license></permissions><abstract><p>This study evaluates the antimicrobial susceptibility and composition of
subgingival biofilms in generalized aggressive periodontitis (GAP) patients
treated using mechanical/antimicrobial therapies, including chlorhexidine (CHX),
amoxicillin (AMX) and metronidazole (MET). GAP patients allocated to the placebo
(C, n = 15) or test group (T, n = 16) received full-mouth disinfection with CHX,
scaling and root planning, and systemic AMX (500 mg)/MET (250 mg) or placebos.
Subgingival plaque samples were obtained at baseline, 3, 6, 9 and 12 months
post-therapy from 3&#x02013;4 periodontal pockets, and the samples were pooled and
cultivated under anaerobic conditions. The minimum inhibitory concentrations
(MICs) of AMX, MET and CHX were assessed using the microdilution method.
Bacterial species present in the cultivated biofilm were identified by
checkerboard DNA-DNA hybridization. At baseline, no differences in the MICs
between groups were observed for the 3 antimicrobials. In the T group,
significant increases in the MICs of CHX (p &#x0003c; 0.05) and AMX (p &#x0003c; 0.01)
were detected during the first 3 months; however, the MIC of MET decreased at 12
months (p &#x0003c; 0.05). For several species, the MICs significantly changed over
time in both groups, <italic>i.e.</italic>, <italic>Streptococci</italic> MICs
tended to increase, while for several periodontal pathogens, the MICs
diminished. A transitory increase in the MIC of the subgingival biofilm to AMX
and CHX was observed in GAP patients treated using enhanced mechanical therapy
with topical CHX and systemic AMX/MET. Both protocols presented limited effects
on the cultivable subgingival microbiota.</p></abstract><kwd-group><kwd>aggressive periodontitis</kwd><kwd>biofilms</kwd><kwd>microbial sensitivity tests</kwd><kwd>DNA probes</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="45"/><page-count count="8"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Generalized aggressive periodontitis (GAP) is a severe form of periodontal disease
characterized by the widespread destruction of the periodontium at a high
progression rate in young subjects (<xref rid="B02" ref-type="bibr">Armitage,
1999</xref>). The adjunctive use of antimicrobials combined with the mechanical
removal of the subgingival biofilm has been demonstrated as an effective therapeutic
strategy for treating GAP (<xref rid="B21" ref-type="bibr">Herrera <italic>et
al.</italic>, 2002</xref>, <xref rid="B22" ref-type="bibr">2008</xref>;
<xref rid="B18" ref-type="bibr">Haffajee <italic>et al.</italic>, 2003</xref>).
Specifically, the administration of amoxicillin (AMX) and metronidazole (MET),
combined or not with the topical use of chlorhexidine (CHX), provides significant
clinical and microbiological benefits for GAP patients post-therapy (<xref rid="B16" ref-type="bibr">Guerrero <italic>et al.</italic>, 2005</xref>). However, some
patients with severe periodontal destruction do not respond favorably to
mechanical/antimicrobial therapy (<xref rid="B06" ref-type="bibr">Colombo <italic>et
al.</italic>, 1998</xref>, <xref rid="B09" ref-type="bibr">2009</xref>).
Treatment failure might have several causes, including the existence of subgingival
microbiota resistant to the drugs of choice (<xref rid="B24" ref-type="bibr">Listgarten <italic>et al.</italic>, 1993</xref>, <xref rid="B25" ref-type="bibr">Mejia <italic>et al.</italic>, 1995</xref>). Antimicrobial
resistance has become a serious problem for the treatment of a large number of
infections worldwide. The inappropriate and irrational use of antimicrobials leads
to the emergence, spread and persistence of resistant microorganisms, resulting in
prolonged illness and greater risk of death (<xref rid="B17" ref-type="bibr">Gootz,
2010</xref>). Thus, an effective antimicrobial protocol for treating
periodontitis should consider the severity of the disease, the general health of the
host, the target microorganisms, and the pharmacokinetics, adverse effects and costs
of the drug (<xref rid="B33" ref-type="bibr">Seymour and Hogg, 2008</xref>, <xref rid="B19" ref-type="bibr">Heasman <italic>et al.</italic>, 2011</xref>).
Moreover, periodontal diseases are polymicrobial, and biofilm-related infections
widely vary in microbial composition and diversity among sites and individuals with
similar clinical manifestations (<xref rid="B39" ref-type="bibr">Socransky and
Haffajee, 2002</xref>). Bacterial species growing in biofilms are less
susceptible to antimicrobial action (<xref rid="B10" ref-type="bibr">Costerton
<italic>et al.</italic>, 1999</xref>). Nevertheless, few studies have
directly examined the <italic>in vitro</italic> antimicrobial susceptibility of
subgingival plaques in biofilms or mixed cultures (Wright <italic>et al.</italic>,
1997, <xref rid="B12" ref-type="bibr">Eick <italic>et al.</italic>, 2004</xref>,
<xref rid="B31" ref-type="bibr">Sedlacek and Walker, 2007</xref>). This
assessment could provide additional information on the susceptibility of periodontal
microbiota in GAP prior to the use of antimicrobials. Furthermore, subsequent
evaluation of the drug administration might reveal potential changes in the
resistance profile of this microbiota. Thus, the aims of the current study were to
determine the bacterial composition and antimicrobial susceptibility profile of the
subgingival biofilm in GAP patients before and up to 12 months after treatment with
CHX, AMX, MET or placebo.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec><title>Subject population</title><p>This study was conducted as a randomized, double-blinded, placebo-controlled,
single-center, 12-month clinical trial as previously described (<xref rid="B20" ref-type="bibr">Heller <italic>et al.</italic>, 2011</xref>, <xref rid="B43" ref-type="bibr">Varela <italic>et al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et al.</italic>, 2013</xref>). The study
protocol was approved through the Ethics in Human Research Committee of the
Institute for Community Health Studies at the Federal University of Rio de
Janeiro, Brazil (EHRC/ICHS-FURJ, protocol #45/2007). The subjects were selected
between March 2008 and June 2009 from a pool of first-time patients referred to
the Division of Graduate Periodontics of the School of Dentistry at the Federal
University of Rio de Janeiro (UFRJ), Brazil. Included patients were diagnosed
with GAP according to criteria of the American Academy of Periodontology (<xref rid="B02" ref-type="bibr">Armitage, 1999</xref>). In addition, the patients
were between 18&#x02013;39 years of age and had at least 16 teeth and 4 sites on
different teeth (3 sites other than central incisors or first molars), with a
probing pocket depth (PPD) &#x02265; 6 mm and clinical attachment level (CAL) &#x02265; 5 mm and
bleeding on probing (BOP). The exclusion criteria were allergy to penicillin,
MET or CHX; diabetes; immunodeficiency; required antibiotic coverage for
periodontal procedures; long-term use of anti-inflammatory medication;
periodontal treatment and/or use of antibiotics in the last 6 months; and
pregnancy and nursing (<xref rid="B20" ref-type="bibr">Heller <italic>et
al.</italic>, 2011</xref>, <xref rid="B43" ref-type="bibr">Varela
<italic>et al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et al.</italic>, 2013</xref>).</p></sec><sec><title>Clinical examination and treatment protocols</title><p>A trained and calibrated examiner (D. H.) performed clinical exams at baseline,
3, 6, 9 and 12 months post-therapy. The full-mouth clinical measurements
included PPD, CAL, presence or absence of BOP, supragingival visible plaque and
gingival marginal bleeding. An experienced periodontist (V.M.C.) administered
periodontal treatment. The patients received full-mouth debridement with
ultrasonics, complemented by the irrigation of all pockets with a 0.2% CHX gel
within 24 h. Additionally, patients were instructed to rinse and gargle twice a
day with a 0.12% CHX solution and brush the tongue with the same CHX gel for the
next 45 days. The patients were subsequently assigned either to the test (T,
systemic administration of AMX 500 mg + MET 250 mg) or the control group (C,
placebo tablets). Antimicrobials or placebos were prescribed 3 times a day for
10 days, starting at the moment of assignment. In the following week, the
patients were treated with staged quadrant manual scaling and root planning,
followed by pocket irrigation with 0.2% CHX gel within 4&#x02013;6 weeks. The patients
returned at 3, 6, 9 and 12 months for clinical re-evaluation, microbiological
sampling, oral hygiene evaluation, and supragingival plaque and calculus
removal. Furthermore, sites with PPD &#x0003e; 4 mm and BOP were re-instrumented
under local anesthesia (<xref rid="B20" ref-type="bibr">Heller <italic>et
al.</italic>, 2011</xref>, <xref rid="B43" ref-type="bibr">Varela
<italic>et al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et al.</italic>, 2013</xref>).</p></sec><sec><title>Subgingival biofilm sampling</title><p>Subgingival biofilm samples were collected from 3&#x02013;4 of the deepest sites (PPD)
using individual sterile Gracey curettes (Hu-Friedy, Chicago, IL, USA). The
material was pooled, placed into cryogenic tubes containing 1 mL of mycoplasma
broth with 10% DMSO and stored at &#x02212;20 &#x000b0;C.</p></sec><sec><title>Determination of the MIC</title><p>Susceptibility testing was performed using the broth microdilution method
according to the Clinical and Laboratory Standards Institute guidelines (<xref rid="B05" ref-type="bibr">CLSI, formerly NCCLS, 2004</xref>), with
modifications. The pooled samples were anaerobically cultured in pre-reduced
supplemented BHI broth (BBL) for 48 h at 37 &#x000b0;C. The mixed culture was
centrifuged, and the bacterial suspension was subsequently adjusted to ~1.5 &#x000d7;
10<sup>8</sup> colony forming units (cfu)/mL in saline solution (0.9%). A
10-&#x003bc;L aliquot of the suspension was dispensed into the wells of 96-well,
round-bottom microtiter plates (TPP), containing 100 &#x003bc;L of two-fold serial
dilutions of the AMX and MET antimicrobials (Sigma-Aldrich Co.). The
antimicrobials were administered at final concentrations ranging from 128 to
0.25 &#x003bc;g/mL for AMX and MET. For CHX, 22 &#x003bc;L of the bacterial suspensions were
placed into wells containing 88 &#x003bc;L of the antimicrobials diluted in
PRAS-supplemented BHI broth to final concentrations ranging from 2% to 0.02%.
Each microplate included positive (bacterial suspension without antimicrobial
treatment) and negative controls (medium only), and all experiments were
performed in duplicate. The microplates were incubated under anaerobic
conditions for 48 h at 37 &#x000b0;C. One examiner obtained visual readings. The MIC was
defined as the lowest antimicrobial concentration yielding no visual bacterial
growth.</p></sec><sec><title>Determination of the Composition of the Subgingival Biofilm through
Checkerboard DNA-DNA Hybridization</title><p>The composition of the subgingival biofilm samples cultivated in the microplates
without antimicrobials (positive controls) at baseline, 3, 6, 9 and 12 months
after treatment was determined using the checkerboard method (<xref rid="B37" ref-type="bibr">Socransky <italic>et al.</italic>, 1994</xref>), with
modifications (<xref rid="B20" ref-type="bibr">Heller <italic>et al.</italic>,
2011</xref>).</p></sec><sec><title>Statistical analysis</title><p>A statistical program (SPSS, Statistical Package for the Social Sciences, version
19.0, IBM) was used for all analyses. The clinical and demographic features of
the groups were compared using the Mann-Whitney and Chi-square tests. The MICs
of each antimicrobial for each patient was averaged within the groups at all
time points. Significant differences between groups and over time were examined
using the Mann-Whitney, Friedman and Wilcoxon signed rank tests. For the
checkerboard data, the levels of each species were computed for each sample and
patient and averaged within each group. For graphic presentation, the levels
(scores 0 to 5) of each species in a sample were converted to absolute numbers
and log10 transformed. Comparisons between groups over time were evaluated using
the Mann-Whitney and Friedman tests, whereas the differences between two time
points were assessed using the Wilcoxon signed rank test. For the checkerboard
analysis, adjustments for multiple comparisons were made according to <xref rid="B36" ref-type="bibr">Socransky <italic>et al.</italic> (1991)</xref>.
Briefly, an overall p of 0.05 = 1 &#x02212; (1 &#x02212; k)<sup>54</sup> was computed, where k
was the desired individual p value. Thus, a p value &#x0003c; 0.00095 was considered
to be statistically significant at p &#x0003c; 0.05. The level of significance for
all the other analyses was 5%.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Information on adverse events, adherence to the local and systemic antimicrobial
regimen, and the demographic and full-mouth periodontal clinical features of the
subjects in both therapeutic groups has been published elsewhere (<xref rid="B20" ref-type="bibr">Heller <italic>et al.</italic>, 2011</xref>, <xref rid="B43" ref-type="bibr">Varela <italic>et al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et al.</italic>, 2013</xref>). The MICs for
the three antimicrobials in subgingival biofilm samples obtained from GAP patients
before and up to 1 year after both treatment protocols are shown in <xref rid="f01" ref-type="fig">Figures 1A&#x02013;C</xref>. At baseline, no significant differences
between groups were observed for the MICs of all tested antimicrobials (p &#x0003e; 0.05,
Mann-Whitney test). However, significant increases in the MICs of CHX (p &#x0003c; 0.05,
<xref rid="f01" ref-type="fig">Figure 1A</xref>) and AMX (p &#x0003c; 0.01, <xref rid="f01" ref-type="fig">Figure 1B</xref>) were detected in the T group at 3
months compared with all other time points (Friedman and Wilcoxon tests).
Significant differences over time were also observed for the MIC of MET (p &#x0003c;
0.05, Friedman test), which decreased at 12 months post-therapy in the T group
(<xref rid="f01" ref-type="fig">Figure 1C</xref>). In the C group, no
significant changes in the MICs of any antimicrobial were observed over time
post-therapy (p &#x0003e; 0.05, Friedman test). Moreover, no significant differences in
the MICs of CHX, AMX or MET between groups were detected at 3, 6, 9 and 12 months
post-therapy (p &#x0003e; 0.05, Mann-Whitney test).</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Mean (&#x000b1; SD) of the MICs of chlorhexidine (A), amoxicillin (B) and
metronidazole (C) in the two therapeutic groups at baseline, 3, 6, 9 and 12
months after periodontal therapy. No differences between groups were
observed at any time point (p &#x0003e; 0.05, Mann-Whitney test). Refers to
significant changes over time in the test groups (Friedman test). *p &#x0003c;
0.05 and <sup>&#x02020;</sup>p &#x0003c; 0.01 refer to significant differences between
the 3-month visit and the other time points in the test groups (Wilcoxon
sign rank test).</title></caption><graphic xlink:href="1517-8382-bjm-46-2-493-gf01"/></fig><p>The composition of the subgingival biofilm cultivated <italic>in vitro</italic> from
patients of the two clinical groups is presented in <xref rid="f02" ref-type="fig">Figure 2</xref>. The species were ordered into different microbial complexes
according to <xref rid="B38" ref-type="bibr">Socransky <italic>et al.</italic>
(1998)</xref>. The mean levels of the tested species (<xref rid="t01" ref-type="table">Table 1</xref>) were computed for both groups at each time
point. At baseline, high mean levels of bacteria (4.4 &#x000d7; 10<sup>5</sup> cells) were
detected in both groups, including several periodontal pathogens. No significant
differences between groups regarding bacterial mean levels were observed for any
species at any time point (adjusted p &#x0003c; 0.00095, Mann-Whitney test). When mean
counts of these species were evaluated within each group over time, few significant
changes were observed (<xref rid="f02" ref-type="fig">Figure 2</xref>). The numbers
of <italic>Streptococcus</italic> spp. increased, while the number of periodontal
pathogens, such as <italic>Agreggatibacter actinomycetemcomitans</italic>,
<italic>Tannerella forsythia</italic>, <italic>Parvimonas micra</italic> and
<italic>Treponema socranskii</italic>, diminished in both groups. However, only
<italic>Streptococcus gordonii</italic> and <italic>Streptococcus
oralis</italic> increased, whereas <italic>Neisseria gonorrhoeae</italic>
significantly decreased at 12 months after treatment in the control group (Friedman
test, p &#x0003c; 0.00095). In the test group, <italic>Actinomyces israelli</italic>,
<italic>Bacteroides fragilis</italic>, <italic>N. gonorrhoeae</italic> and
<italic>Neisseria mucosa</italic> were reduced, and <italic>Acinetobacter
baumannii</italic>, <italic>Campylobacter rectus</italic>, <italic>Filifactor
alocis</italic>, <italic>Salmonella enterica</italic> and <italic>Streptococcus
pneumoniae</italic> significantly increased over time post-therapy (Friedman
test, p &#x0003c; 0.00095).</p><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mean levels of bacterial species in the subgingival biofilm cultivated
<italic>in vitro</italic> from GAP subjects treated using mechanical
therapy associated with CHX and AMX combined with MET (test group) or
placebo (control group) at baseline, 3, 6, 9 and 12 months post-therapy. No
significant differences between groups were observed for any species at any
time point, after adjusting for multiple comparisons (Mann-Whitney test, p
&#x0003e; 0.00095). *Refers to significant changes in bacterial levels over time
in the control group, and <sup>&#x02020;</sup> refers to significant changes in
bacterial levels over time in the test groups (Friedman test, p &#x0003c;
0.00095). The species were ordered into different microbial complexes
according to <xref rid="B38" ref-type="bibr">Socransky <italic>et
al.</italic> (1998)</xref>.</title></caption><graphic xlink:href="1517-8382-bjm-46-2-493-gf02"/></fig><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Bacterial taxa used for development of whole genomic DNA probes tested
against subgingival biofilm samples.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1">Species</th><th valign="bottom" align="center" rowspan="1" colspan="1">Strain<xref rid="TFN01" ref-type="table-fn">*</xref>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Aggregatibacter actinomycetemcomitans a</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43718</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Aggregatibacter actinomycetemcomitans b</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">29523</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Aggregatibacter actinomycetemcomitans c</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">625<sup>b</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces gerensceriae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">23860</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces israelli</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">12102</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces odontolyticus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">17929</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces naeslundii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">12104</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces oris</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43146</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Actinomyces meyeri</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">35568</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Acinetobacter baumannii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">19606</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Bacteroides fragilis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">25285</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Capnocytophaga gingivalis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33624</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Capnocytophaga ochracea</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33596</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Campylobacter rectus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33238</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Campylobacter showae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">51146</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Clostridium difficile</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">98689</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Dialister pneumosintes</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">GBA27<sup>b</sup>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Eubacterium nodatum</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33099</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Eubacterium saburreum</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33271</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Eikenella corrodens</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">23834</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Enterococcus faecalis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Escherichia coli</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10799</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Enterobacter cloacae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10699</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Enterobacter sakazakii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">12868</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Enterobacter aerogenes</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">13048</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Enterobacter gergoviae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33028</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Filifactor alocis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">35896</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Fusobacterium necrophorum</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">25286</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Fusobacterium periodonticum</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33693</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Fusobacterium nucleatum ss. vincentii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">49256</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Haemophilus aphrophilus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33389</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Helicobacter pylori</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43504</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Klebsiella pneumoniae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10031</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Klebsiella oxytoca</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">12833</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria polysaccharea</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43768</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria sicca</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">29256</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria subflava</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">49275</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria meningitidis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">13077</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria lactamica</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">23970</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria gonorrhoeae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">21824</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Neisseria mucosa</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">19696</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Pantoea agglomerans</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">27155</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Parvimonas micra</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33270</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Prevotella melaninogenica</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">25845</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Porphyromonas gingivalis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33277</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Prevotella intermedia</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">25611</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Prevotella nigrescens</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33563</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Propionibacterium acnes I</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">11827</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Propionibacterium acnes II</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43541</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Peptostreptococcus anaerobius</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">27337</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Prevotella tannerae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">51259</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Pseudomonas aeruginosa</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10145</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Rothia dentocariosa</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">17931</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Selenomonas noxia</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33359</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus anginosus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33397</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus constellatus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">27823</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus mitis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">49456</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus oralis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">35037</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus sanguinis</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10556</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus gordonii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10558</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus intermedius</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">27335</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Salmonella enterica sorv. typhi</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">6539</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Staphylococcus aureus</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33591</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Streptococcus pneumoniae</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">49619</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Tannerella forsythia</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">43037</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Treponema denticola</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">B1<xref rid="TFN02" ref-type="table-fn">&#x02020;</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Treponema socranskii</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">S1<xref rid="TFN02" ref-type="table-fn">&#x02020;</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Veillonella parvula</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">10790</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>*</label><p>ATCC (American Type Culture Collection, Rockville, MD)</p></fn><fn id="TFN02"><label>&#x02020;</label><p>The Forsyth Institute, (Boston, MA).</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>The use of systemic antimicrobials as adjunct treatments to mechanical therapy in GAP
is controversial. There are no specific antimicrobial therapy protocols for treating
different forms of periodontitis, and among the currently employed protocols, none
of these therapies completely eliminated the need for retreatment (<xref rid="B21" ref-type="bibr">Herrera <italic>et al.</italic>, 2002</xref>, <xref rid="B22" ref-type="bibr">2008</xref>; <xref rid="B18" ref-type="bibr">Haffajee <italic>et
al.</italic>, 2003</xref>). The systemic administration of antimicrobials
should always consider the risk-benefits for the patients, particularly the costs
and adverse effects of additional drugs (<xref rid="B33" ref-type="bibr">Seymour and
Hogg, 2008</xref>, <xref rid="B19" ref-type="bibr">Heasman <italic>et
al.</italic>, 2011</xref>). In general, the restricted use of systemic
antimicrobials is the best strategy to avoid the increase in resistance worldwide
(<xref rid="B13" ref-type="bibr">Enne, 2010</xref>). Thus, alternative
approaches of intensive mechanical debridement combined with topical antimicrobials,
such as CHX, have been attempted for treating severe forms of periodontitis (<xref rid="B28" ref-type="bibr">Quirynen <italic>et al.</italic>, 1995</xref>; <xref rid="B35" ref-type="bibr">Sigusch <italic>et al.</italic>, 2005</xref>). In
previous studies (<xref rid="B20" ref-type="bibr">Heller <italic>et al.</italic>,
2011</xref>, <xref rid="B43" ref-type="bibr">Varela <italic>et al.</italic>,
2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et
al.</italic>, 2013</xref>), we compared the clinical and microbiological
efficacy of an enhanced non-surgical mechanical therapy with the extensive use of
topical CHX associated with systemic AMX and MET or placebos for up to one year. The
findings indicated that both therapeutic approaches were efficient in improving
clinical parameters and reducing periodontal pathogens. Moreover, we also examined
how these treatments would affect the susceptibility profile and composition of
cultivable subgingival microbiota over time. Conventional <italic>in vitro</italic>
tests of antimicrobial susceptibility are typically performed in planktonic pure
cultures (Wright <italic>et al.</italic>, 1997; <xref rid="B12" ref-type="bibr">Eick
<italic>et al.</italic>, 2004</xref>, <xref rid="B31" ref-type="bibr">Sedlacek and Walker, 2007</xref>), which do not reflect the complex
polymicrobial nature of the subgingival microbiota (<xref rid="B39" ref-type="bibr">Socransky and Haffajee, 2002</xref>). Developing heterotypic biofilm models for
testing antimicrobial agents is a complex task, and the number of different species
co-existing in an <italic>in vitro</italic> model is often limited. Although we did
not employ a mixed biofilm model for evaluating the susceptibility profile, we
directly determined the MICs for the 3 antimicrobials in mixed cultures of
subgingival biofilm samples obtained from each patient pre- and post-therapy using
the microdilution method for anaerobes (NCCLS, 2004). Given that there are no
standardized protocols for antimicrobial testing in anaerobic mixed culture, it is
important to interpret these results with caution. At the pre-therapy phase, we
observed that the susceptibility of the cultivable subgingival microbiota was
similar in both groups. The mean MICs of AMX and CHX were lower than the plasmatic
and gingival crevicular fluid concentrations typically observed after the systemic
administration of 500 mg of AMX 3 times per day (5&#x02013;8 &#x003bc;g/mL) (<xref rid="B23" ref-type="bibr">Kleinfelder <italic>et al.</italic>, 1999</xref>) and the
topical use of CHX (0.12 and 0.2%). In contrast, the MIC of MET was much greater
than the concentrations detected in plasma and gingival crevicular fluid (13&#x02013;14
&#x003bc;g/mL) after a dosage of 500 mg administered 3 times per day (<xref rid="B27" ref-type="bibr">P&#x000e4;hkla <italic>et al.</italic>, 2005</xref>). Other authors have
also reported high MICs for MET in strains of <italic>Prevotella</italic> spp.,
<italic>P. gingivalis</italic>, <italic>Fusobacterium</italic> spp. and
<italic>A. actinomycetemcomitans</italic> isolated from chronic periodontitis
patients in Colombia (<xref rid="B32" ref-type="bibr">Serrano <italic>et
al.</italic>, 2009</xref>, <xref rid="B01" ref-type="bibr">Ardila <italic>et
al.</italic>, 2010</xref>). Moreover, when Spanish and Dutch patients were
compared, higher proportions of <italic>F. nucleatum</italic> and <italic>A.
actinomycetemcomitans</italic> isolates resistant to MET and other commonly used
antimicrobials were observed (<xref rid="B42" ref-type="bibr">Van Winkelhoff
<italic>et al.</italic>, 2000</xref>). The abusive use of antimicrobials and
poor patient compliance, particularly in developing countries (<xref rid="B03" ref-type="bibr">Berquo<italic>et al</italic>., 2004</xref>), may be responsible
for the variability in the susceptibility of the periodontal microbiota in subjects
from distinct populations, suggesting that a single antimicrobial protocol to treat
periodontitis might not be adequate for all patients (<xref rid="B41" ref-type="bibr">Teles <italic>et al.</italic>, 2006</xref>). However, the narrow
spectrum of MET for strict anaerobes (<xref rid="B33" ref-type="bibr">Seymour and
Hogg, 2008</xref>) might limit the <italic>in vitro</italic> effect of this drug
on the mixed culture of subgingival plaques.</p><p>After systemic treatment with AMX and MET, a significant but transitory increase in
the MICs of AMX and CHX was observed in the T group. Although a similar pattern was
detected in the placebo group, the changes in the MICs of all antimicrobials over
time were not significant for this group. Interestingly, topical CHX was extensively
used in both groups, but the increase in the MIC of this antimicrobial was
significant only in the T group. Conceivably, the systemic administration of AMX
and/or MET might have a synergistic impact on the susceptibility of the microbiota
to CHX, reflecting ecological shifts in the periodontal microbiota. Other studies
have also reported the selective and transient pressure of systemic antimicrobials
on the susceptibility of the subgingival microbiota (<xref rid="B14" ref-type="bibr">Feres <italic>et al.</italic>, 2001</xref>, <xref rid="B04" ref-type="bibr">Buchmann <italic>et al.</italic>, 2003</xref>, <xref rid="B30" ref-type="bibr">Rodrigues <italic>et al.</italic>, 2004</xref>). A decrease in the MIC of MET
was observed in both groups, although the concentrations remained high at 12 months
after treatment. The unusual occurrence of resistance to MET has been associated
with technical problems during cultivation under anaerobic conditions (<xref rid="B29" ref-type="bibr">Roberts, 2002</xref>, <xref rid="B11" ref-type="bibr">Diniz <italic>et al.</italic>, 2004</xref>). Nevertheless, genes associated
with MET resistance have been determined in <italic>Bacteroides</italic> spp.
(Trinh<italic>et al</italic>., 1996). In addition, periodontal pathogens
cultivated in biofilms are 100 times more resistant to MET compared with planktonic
cultures (Wright <italic>et al.</italic>, 1997; <xref rid="B12" ref-type="bibr">Eick
<italic>et al.</italic>, 2004</xref>; <xref rid="B31" ref-type="bibr">Sedlacek and Walker, 2007</xref>).</p><p>The composition of the cultivable periodontal microbiota was evaluated before and
after treatment in both groups. At baseline, high levels of many of the tested
bacterial species, including periodontal pathogens, were detected in the
periodontitis-related biofilm in both groups, consistent with previous studies
(<xref rid="B38" ref-type="bibr">Socransky <italic>et al.</italic>, 1998</xref>,
<xref rid="B39" ref-type="bibr">Socransky and Haffajee, 2002</xref>, <xref rid="B40" ref-type="bibr">2005</xref>). In general, an increase in
<italic>Streptococcus</italic> spp. and a reduction of several pathogenic
species in the T and C groups were observed. These changes are consistent with the
establishment of a microbiota compatible with periodontal health following
mechanical therapy with or without the use of systemic antimicrobials (<xref rid="B08" ref-type="bibr">Colombo <italic>et al.</italic>, 2005</xref>, <xref rid="B41" ref-type="bibr">Teles <italic>et al.</italic>, 2006</xref>). Regarding
non-oral bacterial pathogens, the T group presented a significant increase in the
levels of several of these species (<italic>A. baumannii</italic>, <italic>F.
alocis</italic>, <italic>S. enterica</italic> and <italic>S.
pneumoniae</italic>) over time. Many of these microorganisms have been associated
with nosocomial infections, biofilm infections and multi-resistance to antimicrobial
agents. The therapeutic protocols used in the present study might be more effective
against oral pathogens, but these methods might also have a limited effect on other
non-oral pathogenic bacteria. The role of these species in the etiology and
pathogenesis of periodontitis is unclear, although these bacteria have been
frequently detected in the subgingival biofilms of subjects with periodontal
diseases (<xref rid="B06" ref-type="bibr">Colombo <italic>et al.</italic>,
1998</xref>, <xref rid="B07" ref-type="bibr">2002</xref>, <xref rid="B09" ref-type="bibr">2009</xref>; <xref rid="B15" ref-type="bibr">Fritschi<italic>et
al</italic>., 2008</xref>, <xref rid="B20" ref-type="bibr">Heller <italic>et
al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem
<italic>et al.</italic>, 2013</xref>). The presence of these pathogens in
subgingival biofilms might also have medical implications, as pathogenic species
colonizing the periodontal biofilm might be more resistant to antimicrobials.
Previous studies have suggested that major clinical and microbiological changes
after mechanical therapy with or without antimicrobials are typically more
pronounced in the first 3 months after therapy (<xref rid="B44" ref-type="bibr">Xajigeorgiou <italic>et al.</italic>, 2006</xref>, <xref rid="B26" ref-type="bibr">Mestnik <italic>et al.</italic>, 2010</xref>, <xref rid="B45" ref-type="bibr">Yek <italic>et al.</italic>, 2010</xref>). However, as shown in
<xref rid="f02" ref-type="fig">figure 2</xref>, a few species continued to
diminish after 9 and 12 months in both groups. For example, <italic>A.
actinomycetemcomitans</italic> and <italic>P. nigrescens</italic> were not
detected in the cultivated biofilm at 9 and 12 months after both treatment
protocols. The reinforcement in oral hygiene and re-instrumentation during the
monitoring visits might have contributed to the continuous reduction of certain
pathogenic species.</p><p>Thus, these data indicate that enhanced mechanical periodontal therapy associated
with the extensive topical use of CHX and systemic administration of AMX and MET
leads to a transitory increase in the MICs of the subgingival biofilm to AMX and
CHX. Notably, resistance was not evaluated in the present study because there are no
breakpoints to assess susceptibility or resistance when MICs are obtained upon
biofilm analysis. Both therapeutic protocols presented similar and limited effects
on the composition of the cultivable subgingival microbiota over time. Given the
similar clinical benefits of both approaches (<xref rid="B20" ref-type="bibr">Heller
<italic>et al.</italic>, 2011</xref>, <xref rid="B43" ref-type="bibr">Varela
<italic>et al.</italic>, 2011</xref>, <xref rid="B34" ref-type="bibr">Silva-Senem <italic>et al.</italic>, 2013</xref>), the enhanced mechanical
periodontal therapy associated with the topical use of CHX may be suggested as a
potential and effective alternative for the treatment of individuals with GAP,
without major implications on the susceptibility profile of the periodontal
microbiota.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported in part through funding from the National Council for
Scientific and Technological Development (CNPq), Coordination of Improvement of
Higher Education Personnel (CAPES), Brasilia, Brazil, and the Foundation for
Research Financial Support in the State of Rio de Janeiro (FAPERJ), Rio de Janeiro,
Brazil.</p></ack><ref-list><title>References</title><ref id="B01"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardila</surname><given-names>CM</given-names></name><name><surname>Granada</surname><given-names>MI</given-names></name><name><surname>Guzm&#x000e1;n</surname><given-names>IC</given-names></name></person-group><year>2010</year><article-title>Antibiotic resistance of subgingival species in chronic
periodontitis patients</article-title><source>J Period Res</source><volume>45</volume><fpage>557</fpage><lpage>563</lpage></element-citation></ref><ref id="B02"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armitage</surname><given-names>G</given-names></name></person-group><year>1999</year><article-title>Development of a classification system for periodontal diseases
and conditions</article-title><source>Ann Periodontol</source><volume>4</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10863370</pub-id></element-citation></ref><ref id="B03"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berquo</surname><given-names>LS</given-names></name><name><surname>Barros</surname><given-names>AJ</given-names></name><name><surname>Lima</surname><given-names>RC</given-names></name><etal/></person-group><year>2004</year><article-title>Use of antimicrobial drugs in an urban population</article-title><source>Rev Saude Publica</source><volume>38</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">15122380</pub-id></element-citation></ref><ref id="B04"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchmann</surname><given-names>R</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>RF</given-names></name><name><surname>Van Dyke</surname><given-names>TE</given-names></name><etal/></person-group><year>2003</year><article-title>Change of antibiotic susceptibility following periodontal
therapy. A pilot study in aggressive periodontal disease</article-title><source>J Clin Periodontol</source><volume>30</volume><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">12631180</pub-id></element-citation></ref><ref id="B05"><element-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical and Laboratory Standards Institute</collab></person-group><year>2004</year><source>Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria;
approved standard</source><comment>Document M11-A6</comment><edition>6th ed</edition><publisher-name>CLSI</publisher-name><publisher-loc>Wikler, MA</publisher-loc></element-citation></ref><ref id="B06"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>AP</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Dewhirst</surname><given-names>FE</given-names></name><etal/></person-group><year>1998</year><article-title>Clinical and microbiological features of refractory periodontitis
subjects</article-title><source>J Clin Periodontol</source><volume>25</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">9495617</pub-id></element-citation></ref><ref id="B07"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>AP</given-names></name><name><surname>Teles</surname><given-names>RP</given-names></name><name><surname>Torres</surname><given-names>MC</given-names></name><etal/></person-group><year>2002</year><article-title>Subgingival microbiota of Brazilian subjects with untreated
chronic periodontitis</article-title><source>J Periodontol</source><volume>73</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">11990436</pub-id></element-citation></ref><ref id="B08"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>AP</given-names></name><name><surname>Teles</surname><given-names>RP</given-names></name><name><surname>Torres</surname><given-names>MC</given-names></name><etal/></person-group><year>2005</year><article-title>Effects of non-surgical mechanical therapy on the subgingival
microbiota of Brazilians with untreated chronic periodontitis: 9-month
results</article-title><source>J Periodontol</source><volume>76</volume><fpage>116</fpage><lpage>122</lpage></element-citation></ref><ref id="B09"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>AP</given-names></name><name><surname>Boches</surname><given-names>SK</given-names></name><name><surname>Cotton</surname><given-names>SL</given-names></name><etal/></person-group><year>2009</year><article-title>Comparisons of subgingival microbial profiles of refractory
periodontitis, severe periodontitis, and periodontal health using the human
oral microbe identification microarray</article-title><source>J Periodontol</source><volume>80</volume><fpage>1421</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">19722792</pub-id></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costerton</surname><given-names>JW</given-names></name><name><surname>Stewart</surname><given-names>PS</given-names></name><name><surname>Greenberg</surname><given-names>EP</given-names></name></person-group><year>1999</year><article-title>Bacterial biofilms: a common cause of persistent
infections</article-title><source>Science</source><volume>284</volume><fpage>1318</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">10334980</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diniz</surname><given-names>CG</given-names></name><name><surname>Farias</surname><given-names>LM</given-names></name><name><surname>Carvalho</surname><given-names>MA</given-names></name><etal/></person-group><year>2004</year><article-title>Differential gene expression in a <italic>Bacteroides
fragilis</italic> metronidazole-resistant mutant</article-title><source>J Antimicr Chemoth</source><volume>54</volume><fpage>100</fpage><lpage>108</lpage></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eick</surname><given-names>S</given-names></name><name><surname>Seltmann</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>W</given-names></name></person-group><year>2004</year><article-title>Efficacy of antibiotics to strains of periodontopathogenic
bacteria within a single species biofilm - an in vitro study</article-title><source>J Clin Periodontol</source><volume>31</volume><fpage>376</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">15086620</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enne</surname><given-names>VI</given-names></name></person-group><year>2010</year><article-title>Reducing antimicrobial resistance in the community by restricting
prescribing: can it be done?</article-title><source>J Anti Chemo</source><volume>65</volume><fpage>179</fpage><lpage>182</lpage></element-citation></ref><ref id="B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feres</surname><given-names>M</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Allard</surname><given-names>KA</given-names></name><etal/></person-group><year>2001</year><article-title>Change in subgingival microbial profiles in adult periodontitis
subjects receiving either systemically administered amoxicillin or
metronidazole</article-title><source>J Clin Periodontol</source><volume>28</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">11422580</pub-id></element-citation></ref><ref id="B15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritschi</surname><given-names>BZ</given-names></name><name><surname>Albert-Kiszely</surname><given-names>A</given-names></name><name><surname>Persson</surname><given-names>GR</given-names></name></person-group><year>2008</year><article-title>
<italic>Staphylococcus aureus</italic> and other bacteria in
untreated periodontitis</article-title><source>J Dent Res</source><volume>87</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">18502971</pub-id></element-citation></ref><ref id="B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>A</given-names></name><name><surname>Griffiths</surname><given-names>GS</given-names></name><name><surname>Nibali</surname><given-names>L</given-names></name><etal/></person-group><year>2005</year><article-title>Adjunctive benefits of systemic amoxicillin and metronidazole in
non-surgical treatment of generalized aggressive periodontitis: a randomized
placebo-controlled clinical trial</article-title><source>J Clin Periodontol</source><volume>32</volume><fpage>1096</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">16174275</pub-id></element-citation></ref><ref id="B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gootz</surname><given-names>TD</given-names></name></person-group><year>2010</year><article-title>The global problem of antibiotic resistance</article-title><source>Crit Rev Immunol</source><volume>30</volume><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">20370622</pub-id></element-citation></ref><ref id="B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Gunsolley</surname><given-names>JC</given-names></name></person-group><year>2003</year><article-title>Systemic anti-infective periodontal therapy. A systematic
review</article-title><source>Ann Periodontol</source><volume>8</volume><fpage>115</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">14971252</pub-id></element-citation></ref><ref id="B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heasman</surname><given-names>PA</given-names></name><name><surname>Vernazza</surname><given-names>CR</given-names></name><name><surname>Gaunt</surname><given-names>FL</given-names></name><etal/></person-group><year>2011</year><article-title>Cost-effectiveness of adjunctive antimicrobials in the treatment
of periodontitis</article-title><source>Periodontol 2000</source><volume>55</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">21134237</pub-id></element-citation></ref><ref id="B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Varela</surname><given-names>VM</given-names></name><name><surname>Silva-Senem</surname><given-names>MX</given-names></name><etal/></person-group><year>2011</year><article-title>Impact of systemic antimicrobials combined to anti-infective
mechanical debridement on the microbiota of generalized aggressive
periodontitis: a 6-month RCT</article-title><source>J Clin Periodontol</source><volume>38</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">21303403</pub-id></element-citation></ref><ref id="B21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>D</given-names></name><name><surname>Sanz</surname><given-names>M</given-names></name><name><surname>Jepsen</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>A systematic review on the effect of systemic antimicrobials as
an adjunct to scaling and root planning in periodontitis
patients</article-title><source>J Clin Periodontol</source><volume>29</volume><fpage>136</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">12787214</pub-id></element-citation></ref><ref id="B22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>B</given-names></name><name><surname>Le&#x000f3;n</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>Antimicrobial therapy in periodontitis: the use of systemic
antimicrobials against the subgingival biofilm</article-title><source>J Clin Periodontol</source><volume>35</volume><fpage>45</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18724841</pub-id></element-citation></ref><ref id="B23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinfelder</surname><given-names>JW</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>RF</given-names></name><name><surname>Lange</surname><given-names>DE</given-names></name></person-group><year>1999</year><article-title>Antibiotic susceptibility of putative periodontal pathogens in
advanced periodontitis patients</article-title><source>J Clin Periodontol</source><volume>26</volume><fpage>347</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">10382573</pub-id></element-citation></ref><ref id="B24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Listgarten</surname><given-names>MA</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Young</surname><given-names>V</given-names></name></person-group><year>1993</year><article-title>Microbial composition and pattern of antibiotic resistance in
subgingival microbial samples from patients with refractory
periodontitis</article-title><source>J Periodontol</source><volume>64</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">8463936</pub-id></element-citation></ref><ref id="B25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mejia</surname><given-names>GI</given-names></name><name><surname>Botero</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>W</given-names></name><etal/></person-group><year>1995</year><article-title>Refractory periodontitis in a Colombian population: Predominant
anaerobic bacterial flora and antibiotic susceptibility</article-title><source>Clin Infect Dis</source><volume>20</volume><fpage>311</fpage><lpage>313</lpage></element-citation></ref><ref id="B26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestnik</surname><given-names>MJ</given-names></name><name><surname>Feres</surname><given-names>M</given-names></name><name><surname>Figueiredo</surname><given-names>L</given-names></name><etal/></person-group><year>2010</year><article-title>Short-term benefits of the adjunctive use of metronidazole plus
amoxicillin in the microbial profile and in the clinical parameters of
subjects with generalized aggressive periodontitis</article-title><source>J Clin Periodontol</source><volume>37</volume><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">20447259</pub-id></element-citation></ref><ref id="B27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e4;hkla</surname><given-names>ER</given-names></name><name><surname>Koppel</surname><given-names>T</given-names></name><name><surname>Saag</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Metronidazole concentrations in plasma, saliva and periodontal
pockets in patients with periodontitis</article-title><source>J Clin Periodontol</source><volume>32</volume><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">15691346</pub-id></element-citation></ref><ref id="B28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quirynen</surname><given-names>M</given-names></name><name><surname>Bollen</surname><given-names>CM</given-names></name><name><surname>Vandekerckhove</surname><given-names>BN</given-names></name><etal/></person-group><year>1995</year><article-title>Full- <italic>vs</italic>. partial-mouth disinfection in the
treatment of periodontal infections: short-term clinical and microbiological
observations</article-title><source>J Dent Res</source><volume>74</volume><fpage>1459</fpage><lpage>1467</lpage><pub-id pub-id-type="pmid">7560400</pub-id></element-citation></ref><ref id="B29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>MC</given-names></name></person-group><year>2002</year><article-title>Antibiotic toxicity, interactions and resistance
development</article-title><source>Periodontol 2000</source><volume>28</volume><fpage>280</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">12013346</pub-id></element-citation></ref><ref id="B30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>RMJ</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>C</given-names></name><name><surname>Souto</surname><given-names>R</given-names></name><etal/></person-group><year>2004</year><article-title>Antibiotic resistance profile of the subgingival microbiota
following systemic or local tetracycline therapy</article-title><source>J Clin Periodontol</source><volume>31</volume><fpage>420</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">15142209</pub-id></element-citation></ref><ref id="B31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedlacek</surname><given-names>MJ</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>Antibiotic resistance in an in vitro subgingival biofilm
model</article-title><source>Oral Microbiol Immunol</source><volume>22</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">17803631</pub-id></element-citation></ref><ref id="B32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>C</given-names></name><name><surname>Torres</surname><given-names>N</given-names></name><name><surname>Valdivieso</surname><given-names>C</given-names></name><etal/></person-group><year>2009</year><article-title>Antibiotic resistance of periodontal pathogens obtained from
frequent antibiotic users</article-title><source>Act Odont Latinoame</source><volume>22</volume><fpage>99</fpage><lpage>104</lpage></element-citation></ref><ref id="B33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seymour</surname><given-names>RA</given-names></name><name><surname>Hogg</surname><given-names>SD</given-names></name></person-group><year>2008</year><article-title>Antibiotics and chemoprophylaxis</article-title><source>Periodontol 2000</source><volume>46</volume><fpage>80</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">18201347</pub-id></element-citation></ref><ref id="B34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva-Senem</surname><given-names>MX</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Varela</surname><given-names>VM</given-names></name><etal/></person-group><year>2013</year><article-title>Clinical and microbiological effects of systemic antimicrobials
combined to an anti-infective mechanical debridement for the management of
aggressive periodontitis: a 12-month randomized controlled
trial</article-title><source>J Clin Periodontol</source><volume>40</volume><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">23297772</pub-id></element-citation></ref><ref id="B35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigusch</surname><given-names>BW</given-names></name><name><surname>G&#x000fc;ntsch</surname><given-names>A</given-names></name><name><surname>Pfitzner</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Enhanced root planing and systemic metronidazole administration
improve clinical and microbiological outcomes in a two-step treatment
procedure</article-title><source>J Periodontol</source><volume>76</volume><fpage>991</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">15948696</pub-id></element-citation></ref><ref id="B36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><etal/></person-group><year>1991</year><article-title>Relation of counts of microbial species to clinical status at the
sampled site</article-title><source>J Clin Periodontol</source><volume>18</volume><fpage>766</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">1661305</pub-id></element-citation></ref><ref id="B37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><etal/></person-group><year>1994</year><article-title>"Checkerboard" DNA-DNA hybridization</article-title><source>Biotech</source><volume>17</volume><fpage>788</fpage><lpage>792</lpage></element-citation></ref><ref id="B38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Cugini</surname><given-names>MA</given-names></name><etal/></person-group><year>1998</year><article-title>Microbial complexes in subgingival plaque</article-title><source>J Clin Periodontol</source><volume>25</volume><fpage>134</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">9495612</pub-id></element-citation></ref><ref id="B39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name></person-group><year>2002</year><article-title>Dental biofilms: difficult therapeutic targets</article-title><source>Periodontol 2000</source><volume>28</volume><fpage>12</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12013340</pub-id></element-citation></ref><ref id="B40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socransky</surname><given-names>SS</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name></person-group><year>2005</year><article-title>Periodontal microbial ecology</article-title><source>Periodontol 2000</source><volume>38</volume><fpage>135</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">15853940</pub-id></element-citation></ref><ref id="B41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teles</surname><given-names>RP</given-names></name><name><surname>Haffajee</surname><given-names>AD</given-names></name><name><surname>Socransky</surname><given-names>SS</given-names></name></person-group><year>2006</year><article-title>Microbiological goals of periodontal therapy</article-title><source>Periodontol 2000</source><volume>42</volume><fpage>180</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16930311</pub-id></element-citation></ref><ref id="B42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Winkelhoff</surname><given-names>AJ</given-names></name><name><surname>Herrera</surname><given-names>GD</given-names></name><name><surname>Winkel</surname><given-names>EG</given-names></name><etal/></person-group><year>2000</year><article-title>Antimicrobial resistance in the subgingival microflora in
patients with adult periodontitis. A comparison between The Netherlands and
Spain</article-title><source>J Clin Periodontol</source><volume>7</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">10703651</pub-id></element-citation></ref><ref id="B43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela</surname><given-names>VM</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Silva-Senem</surname><given-names>MX</given-names></name><etal/></person-group><year>2011</year><article-title>Systemic antimicrobials adjunctive to a repeated mechanical and
antiseptic therapy for aggressive periodontitis: a 6-month randomized
controlled trial</article-title><source>J Periodontol</source><volume>82</volume><fpage>1121</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">21235333</pub-id></element-citation></ref><ref id="B44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xajigeorgiou</surname><given-names>C</given-names></name><name><surname>Sakellari</surname><given-names>D</given-names></name><name><surname>Slini</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Clinical and microbiological effects of different antimicrobials
on generalized aggressive periodontitis</article-title><source>J Clin Periodontol</source><volume>33</volume><fpage>254</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">16553634</pub-id></element-citation></ref><ref id="B45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yek</surname><given-names>EC</given-names></name><name><surname>Cintan</surname><given-names>S</given-names></name><name><surname>Topcuoglu</surname><given-names>N</given-names></name><etal/></person-group><year>2010</year><article-title>Efficacy of amoxicillin and metronidazole combination for the
management of generalized aggressive periodontitis</article-title><source>J Periodontol</source><volume>81</volume><fpage>964</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">20214441</pub-id></element-citation></ref></ref-list></back></article>